Related posts
Nervous markets await NvidiaThis summary was created by AI, based on 17 opinions in the last 12 months.
Abbott Labs (ABT) is currently navigating some challenging legal landscapes while also showing promising growth potential across its diversified business segments, including medical devices and pharmaceuticals. The company has recently experienced positive momentum, with strong quarterly earnings and updated forecasts, countering some of the impacts of lawsuits related to its baby formula products. Experts note its solid fundamentals, particularly within its device business that has demonstrated robust organic growth. Despite facing legal challenges and penalties, many analysts are optimistic about the stock's trajectory in the long term, highlighting its reasonable valuation and consistent dividend growth. Overall, Abbott appears to be positioned well for future gains, even amid current litigation concerns.
Has excellent fundamentals across four businesses, including best-in-class medical devices renown in cardiology. However, they face lawsuits over their similac formula which studies show is not harmful. It's unfair. It lost a lawsuit last summer and was hit a $495 million penalty. More lawsuits are coming, though the latest decision yesterday went in Abbott's favour. Last month, federal agencies found that the formula is not at fault. Two weeks ago, ABT reported a clean top and bottom line beat and raised their full-year forecast. Shares would have rallied more without the lawsuits.
Expects it to growth topline and bottom line going forward, usually around the 10% range. Sells branded generic drugs to EMs, medical devices, infant nutrition. Diabetes monitoring product has very good growth. Likes that it's diversified, well managed. Yield close to 3%, grown for over 50 consecutive years.
Pharma is challenged on growth, whereas devices have robust growth. Its device business has grown exceptionally well, between 10-12% organically. Overhang has been unfavourable comparisons from Covid testing. Reasonable valuation for quite a good company. Yield is 2%.
(Analysts’ price target is $123.65)Abbott Labs is a American stock, trading under the symbol ABT-N on the New York Stock Exchange (ABT). It is usually referred to as NYSE:ABT or ABT-N
In the last year, 4 stock analysts published opinions about ABT-N. 2 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Abbott Labs.
Abbott Labs was recommended as a Top Pick by on . Read the latest stock experts ratings for Abbott Labs.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
4 stock analysts on Stockchase covered Abbott Labs In the last year. It is a trending stock that is worth watching.
On 2025-04-25, Abbott Labs (ABT-N) stock closed at a price of $128.85.
They reported solid numbers today and considered raising their full-year forecast but then the tariffs hit, but maintained guidance, which is positive enough in this market. Shares jumped 2.76% today. A weaker USD helps too.